Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
Open Posted
- Opportunity number
- PAR-27-053
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Category
-
- Health
- Eligible applicants
-
- For Profit Organizations
- Small Businesses
- Higher Education Inst. (Private)
- Public or Indian Housing Auth.
- Special District Governments
- City/Township Governments
- Other
- Higher Education Inst. (Public)
- Non-501(c)(3) Nonprofits
- Tribal Organizations (Not Federally Recognized)
- State Governments
- Independent School Districts
- Tribal Governments (Federally Recognized)
- 501(c)(3) Nonprofits
- County Governments
- Points of contact
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institute on Drug Abuse seeks applicants for the Exploratory Clinical Neuroscience Research on Substance Use Disorders program (R61/R33 Phased Innovation Award), with rolling application deadlines on February 19, 2027; June 17, 2027; October 20, 2027; and February 22, 2028. Applicants must not propose alcohol use disorders as a primary outcome or harm reduction activities.
Eligible applicants include for-profit and nonprofit organizations, higher education institutions (public and private), state and local governments, tribal governments, foreign organizations, and other entity types. Non-domestic components of U.S. organizations and foreign components are eligible; however, NIH will not issue awards involving foreign subawards or subcontracts except under NOFOs specifically designated for international collaborations. Applications proposing foreign subawards or subcontracts submitted to this opportunity will be deemed noncompliant.
The R61 phase (planning phase) is capped at $500,000 in direct costs over up to two years. R33 phase budgets are unrestricted but must reflect actual project needs. The combined maximum project period is five years (two years R61, three years R33). Approximately 50 percent of R61-funded grants are expected to transition to R33 funding upon successful completion of well-defined, quantifiable milestones proposed during the R61 phase.
Research must focus on understanding neurobiological mechanisms underlying substance use disorders, including fundamental circuitry and behavior relevant to substance use. For projects not requiring a phased approach, applicants are encouraged to apply under alternative funding activity codes such as PA-25-305 (Research Project Grant Parent R01).
The review process evaluates scientific and technical merit using scored criteria including importance of research, rigor and feasibility, and expertise and resources, with additional consideration of human subjects protections and vertebrate animal use where applicable. This opportunity is funded under CFDA 93.279 (Drug Use and Addiction Research Programs).
Synopsis
This notice of funding opportunity (NOFO) uses a R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. For projects not requiring a phased research approach, applicants are encouraged to apply under a different funding activity code (e.g., PA-25-305 "Research Project Grant (Parent R01 Clinical Trial Required)" or its subsequent reissue).
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.
Files
| File | Type | Posted |
|---|---|---|
| PKG00294090.pdf | ||
| PAR-27-053-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity